{"ticker": {"uuid": "eb64bade-4c9e-49a5-a30d-539ebca2200e", "symbol": "AMRX", "name": "Amneal Pharmaceuticals, Inc. Class A Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxPa0hVTU9ORHdBVElRSWdfS3FHUzcyZFlCdFh2OC1LekhzUWdKbDdOcTRzNndrTjE2WWVhUGJYbkU5c0h2VW9rQS12b2I5c0hjQXBRYXZQTmoyZXlBMEJEZ0lad1BXMW15WmdtYVVXM1VvZlN4UWNFazB4cmRfVUNQNEdncy1PY2R4cnFMRzhXc2lHbDNMN2tRS095cnlLckJBYTRwOXNMYUZiSk1nM1RZYnRBb01kdkRIZndKenlSTDdqTmRqaWF2d1JpWE5JU3JvQVJ4YlFnUS1lZEZxMFJsRlRzVGltR1ZBd2FDOdIB8gFBVV95cUxQa002bjRoWC1RbE0zMHJjbU5qYWNDQVB5cDU5M3BOdnU2bWRvcVhybXYxWmc1M0Q3RThySlA3c3NkMzlQQVJOakpUMmpYOVNJYkNBamRtdGNTTTdpNm91NzNnVUdCSnVRdDBCUDlmVDNvMzZnTm9PZENUbHpYNkoxZjBzSXlkSVJ5TkpBZ2pqN1J5ZWNTSDFtX2gwcUZnbFN5Q2hMTzBWdURtTW5zX1k5cWlnaGdodzh0SDZWN01RZHB4M29lVlExRjU4NlVoS09vek5WaVBVYW9MMmJEYlVwQjdWQWQ5TnU5UkFQSWZoamhnUQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-21T17:26:16+00:00", "published_display": "21 Jun 2026 17:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/korro-bio-inc-krro-soars-120600350.html", "source_name": "Zacks", "published_at": "2026-06-19T12:06:00+00:00", "published_display": "19 Jun 2026 12:06", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) agrees to buy Kashiv for $375M cash plus equity and milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQMmxra2dRTkc1Mjl1T1BzcktuOUdKVjFRMEJiQkI2NUgxQnk4QlZyQ0lsT3Q0NWQ2S2xOVExkVVlXTlZuOXZ4X2Y5SVZHMVJ2cTd4NUtPZXFTWS1zY2xsMHhVZ25NMG1HdEZTQzg5WE01NkdzTk9mSDZOYUNZdko5YjNXcmhIdVh4V3RqU3UxcE83MFZySU92SkFCeUpENE1MaXJIT1owRE55UGZvbzBQLVBBRjdfRUV5NkNRbWxaTTRLRFNFZFgzY2g2TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T21:00:28+00:00", "published_display": "18 Jun 2026 21:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/1-small-cap-stock-long-111651197.html", "source_name": "StockStory", "published_at": "2026-06-17T11:16:51+00:00", "published_display": "17 Jun 2026 11:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top 3 Health Care Stocks That May Collapse This Quarter", "summary": "The article identifies three healthcare stocks\u2014Cardinal Health, TG Therapeutics, and Amneal Pharmaceuticals\u2014that may be overbought according to the Relative Strength Index (RSI) as of June 15, 2026. Despite recent positive news and stock gains for all three companies, their high ", "url": "https://www.sahmcapital.com/news/content/top-3-health-care-stocks-that-may-collapse-this-quarter-2026-06-15", "source_name": "Sahm", "published_at": "2026-06-15T16:39:17", "published_display": "15 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) Stock Valuation Check After Strong Multi Period Gains And Conflicting Fair Value Models", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals (AMRX) Is Up 17.8% After CREXONT Phase 4 Gains And New Oncology Launch", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/amneal-pharmaceuticals-amrx-17-8-050712031.html", "source_name": "Simply Wall St.", "published_at": "2026-06-13T05:07:12+00:00", "published_display": "13 Jun 2026 05:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals (AMRX) Is Up 19.0% After CREXONT Data And New CGT Oncology Approval - What's Changed", "summary": "Amneal Pharmaceuticals (AMRX) recently saw a 19.0% stock increase following positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson\u2019s disease and FDA approval for its romidepsin injection for cutaneous T-cell lymphoma. These developments reinforce the company's strat", "url": "https://www.sahmcapital.com/news/content/amneal-pharmaceuticals-amrx-is-up-190-after-crexont-data-and-new-cgt-oncology-approval-whats-changed-2026-06-11", "source_name": "Sahm", "published_at": "2026-06-11T14:12:02", "published_display": "11 Jun 2026 14:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD", "summary": "Amneal Pharmaceuticals (AMRX) stock reached a 52-week high of $15.44, experiencing an 88% increase over the past year. This surge is attributed to the company's strong financial performance, including exceeding Q1 2026 earnings and revenue expectations, and key product developmen", "url": "https://www.investing.com/news/company-news/amneal-pharmaceuticals-stock-hits-52week-high-at-1544-usd-93CH-4735567", "source_name": "Investing.com", "published_at": "2026-06-11T12:39:53", "published_display": "11 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQUUh2NHdvREcwdWFlQ3FKakpRS2N0MTdzb2hoQ29RbFBxQnFpcTlJY0JBd2hObGx2X2N1TThZclZsRGVKWlRKT0N4UXZVU2hpLTFsNHBoSkQwS1lSZHFseTNjcjNfNTV6TWFoRXBHV0JBaXlkQXlJYXVzWC0zYzdnbEQyT1JLZHQwRWMyVTZVbkFLQmphd29Db0ZYQW1wa1JIbXZ3?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD By Investing.com", "summary": "Amneal Pharmaceuticals Inc. Class A stock reached a 52-week high of $15.44, trading at $15.45 with a market capitalization of $4.87 billion, reflecting an 88% increase over the past year. This surge is attributed to the company's strong financial health and recent positive develo", "url": "https://ng.investing.com/news/company-news/amneal-pharmaceuticals-stock-hits-52week-high-at-1544-usd-93CH-2552288", "source_name": "Investing.com Nigeria", "published_at": "2026-06-11T07:09:59", "published_display": "11 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dispensary of Hope Launches \"Hope Alliance\" Campaign with Support from Amneal Pharmaceuticals", "summary": "Dispensary of Hope has launched its \"Hope Alliance\" campaign, aimed at expanding access to longer-dated medications for low-income and uninsured patients nationwide. Amneal Pharmaceuticals is the first manufacturer to commit significant support, ensuring a reliable supply of crit", "url": "https://www.sahmcapital.com/news/content/dispensary-of-hope-launches-hope-alliance-campaign-with-support-from-amneal-pharmaceuticals-2026-06-10", "source_name": "Sahm", "published_at": "2026-06-10T14:09:18", "published_display": "10 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase", "summary": "", "url": "https://finance.yahoo.com/m/2b12215f-513a-3347-ac82-994df2ad5b8a/amneal-pharmaceuticals-bets.html", "source_name": "MarketBeat", "published_at": "2026-06-09T19:05:48+00:00", "published_display": "09 Jun 2026 19:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving Amneal's 2026 Growth Outlook?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPcWlSODh4a2RjOFhhSVo2VGNJSGZpUWQ0MmxaREQ5Y3U4NzM5SDQyd3M2aGc1NWIxRVhmdVNrZUI5Rzg0YmpyemFOUG1LamlhR0pTQUZuZ3JpRzBxVk40aHFGXy1TZm9BY0wwMERBNlBfaDdUZThxT2R4N1lSYzh5SEZZNEdWei16V1lFOWRWc0pkMTh5bWxXQkVHMVhxNk1P?oc=5", "source_name": "TradingView", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data", "summary": "Amneal Pharmaceuticals (AMRX) recently received FDA approval for its romidepsin injection and positive interim Phase 4 data for Parkinson's treatment CREXONT, contributing to an 80.45% 1-year total shareholder return. Despite being valued at $13.75 against an estimated fair value", "url": "https://www.sahmcapital.com/news/content/a-look-at-amneal-pharmaceuticals-amrx-valuation-after-romidepsin-approval-and-positive-crexont-trial-data-2026-06-06", "source_name": "Sahm", "published_at": "2026-06-06T10:39:38", "published_display": "06 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/amneal-pharmaceuticals-amrx-story-shifting-050559676.html", "source_name": "Simply Wall St.", "published_at": "2026-06-06T05:05:59+00:00", "published_display": "06 Jun 2026 05:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX)", "summary": "Amneal Pharmaceuticals (AMRX) shares advanced after the company secured FDA clearance for its generic version of a cancer treatment. The approval is for a bendamustine hydrochloride injection, a chemotherapy drug used to treat chronic lymphocytic leukemia and indolent B-cell non-", "url": "https://www.msn.com/en-us/health/other/amneal-pharmaceuticals-advances-after-securing-fda-clearance-for-cancer-treatment-amrx/ar-AA24QznW", "source_name": "MSN", "published_at": "2026-06-05T21:39:58", "published_display": "05 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Stock Up on FDA Nod for Romidepsin Injection Solution", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/amneal-stock-fda-nod-romidepsin-153000754.html", "source_name": "Zacks", "published_at": "2026-06-05T15:30:00+00:00", "published_display": "05 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals stock gains on FDA approval for cancer drug By Investing.com", "summary": "Amneal Pharmaceuticals (NASDAQ:AMRX) shares rose after the FDA approved its romidepsin injection solution for cutaneous T-cell lymphoma, granting 180 days of market exclusivity. This ready-to-use formulation offers an alternative to a previously withdrawn product and generated ap", "url": "https://au.investing.com/news/stock-market-news/amneal-pharmaceuticals-stock-gains-on-fda-approval-for-cancer-drug-93CH-4472078", "source_name": "Investing.com Australia", "published_at": "2026-06-05T10:39:38", "published_display": "05 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals stock gains on FDA approval for cancer drug", "summary": "Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) saw its shares rise in premarket trading after receiving FDA approval for its romidepsin injection solution. This drug, a histone deacetylase inhibitor for cutaneous T-cell lymphoma, offers a ready-to-use alternative and is eligible for 1", "url": "https://m.investing.com/news/stock-market-news/amneal-pharmaceuticals-stock-gains-on-fda-approval-for-cancer-drug-93CH-4726690?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-04T12:09:40", "published_display": "04 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amneal (AMRX) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNa0dfRXF6MXBqZDFYNjRGb2pzNWcwUjdiUFVvMG5CWXFhUmVWdVA3RlkxdnI0YXhxMEtubXNYelgyOVF0LVI4ZDd3TW45akZjT2J6Z0YzcGZtOXNxQWRjZjBUR056R1Rvb1RIdDd4dElheDB4MjhCLTdHLW1aY1pyalZ0RzFqYS1mR0pLMzF4VEt4QWN0VmliaU1GcmowaGZST0xiQ2hjUU5YMlJScmF6Qk0zNm96bE8weTFSTDZXTnk4T2Z3?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal\u2019s Goldman Sachs 2026 healthcare talk to stream live June 9", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOU1E2LWtVMjRlbUZadWppaXltU2hEN19wTW1wVlk3ZzFzam5Pb2NRWjdyVS14TGF4R3RpckIyd1NrZnF2YnVrdExrZ29pNG5QWlpsZE1vU3B0N2EwZUZnYnVocUxLWWp6ZlNpZ0g2ZkNxaVdLSGNaek1uMVlac1hlRnVVWkhOZDVhQ0c2dEdFQV90UVlhbjhHYmVLSFNRU2FTWVN0eWpDOHBHNUkzOUJBek1PS3E0MVYxSk5jczBaSjM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNNWZuNGpuV3hudUNTV1RCZFV5dDlNc2J6YU9YdjNRdm5LS085cWVWMmdtckZITlpETVVjVDNLeTI5U0t1TmdxejQweno3RU5GVDJuQ3dWN2ZMTmZSTVZLY2dSUmhZS0JKeUlJTWthc1MweFlhSTdFU2x2YW9Famh2RHZEVG4tb04yYnRreE82MlBlSlpnRE1jSHllZkFzTGxjeU8wSXZhUTJnMVotcDdj?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Strength And Long Term Gains", "summary": "Amneal Pharmaceuticals (AMRX) has seen recent gains and strong long-term returns, prompting an assessment of its valuation. Simply Wall St estimates a fair value of $17.00, suggesting the stock is currently undervalued at its trading price of $13.17. This bullish outlook is drive", "url": "https://www.sahmcapital.com/news/content/assessing-amneal-pharmaceuticals-amrx-valuation-after-recent-share-price-strength-and-long-term-gains-2026-05-30", "source_name": "Sahm", "published_at": "2026-05-29T09:08:57", "published_display": "29 May 2026 09:08", "sentiment": "positive", "sentiment_pct": 64, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYkpzQXJERWVndUxLQ0xoZHVLR3N5WW1aRjJ1QVVKMHZmZlVfM05XTzY3bjdNVUpiYzVuY19YN0o0MUJHLVREeTdSWmJ4YUhaVXVndXlkX05uNHRBNXdOSm1HbnVKYUpvYmJaUkdfV29lVU9MNjFkRWR0TUhFZnVaOXlwcEZTVndfajR2LVVqRE9VNHpqLUhNT3pfc04tTGVSVjZXNWNBSFE?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQ0ZnM0YtZFBWeGNmVnFZTlBZdVlxbWpWVkZFaGtrcGExZHdjb0t5ZXJRbjBlaVRWd0NybVdvYVAxZVhtSTJEWWFrMDM5T2V0aU9RcFhUcWw5b1QtcHZXcElsR1oxbE92MUlYakQ2U2tNd282S2lPdVB4RGo2aW5Iby1aTXdpN0lIVnFYdk8wRnphb2c3dEkwVWpUajJXSWM4SFYxM1laM3RkMWs?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNZGdxTjJUSWU4cUU5X3ptZ183Q2VyQk43RFZhZXl1REN3V21zckN5RVE5SGFidHZtTTQxeEVXS0hZQjdnNi1QaFNlZXhNbWpaQ2lROUVqdjZxTHl2TmRtQ1c4RWplc2c4NUlFXzdFMzVlV2tBSlQ3LU43Tl9LSFUzLVRPYXNmSUp4dndVS0RQclhqUUpxS3NVZWtPSQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2 Reasons AMRX is Risky and 1 Stock to Buy Instead", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQY2x0ZE5jalpSS0tjam1RNmhuUWpYdnZVVDlfV1lpWnhqUktqcWwzeE94Z3BRcFRTODl4cHVmc0t1V0UwNTRsbHh4MzNqallsVXZqZmU1c3V6UGlURW51bllDZ3J1TjZZREVpR2NFdFRrUlIxQWRZM3pBejAtZ2IxOGVfcTFiZ1Jvc2JoNk45VlQ?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Amneal Pharmaceuticals, Inc. SEC Filing", "summary": "This article details an SEC Form 144 filing by Amneal Pharmaceuticals, Inc. (AMRX). The filing indicates a proposed sale of 34,819 shares of Class A Common Stock by an individual through Merrill Lynch on May 11, 2026, with an aggregate market value of 450,416. The shares were acq", "url": "https://www.stocktitan.net/sec-filings/AMRX/144-amneal-pharmaceuticals-inc-sec-filing-1cabdad0fc62.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:40:23", "published_display": "13 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness", "summary": "Amneal Pharmaceuticals (AMRX) has experienced mixed share performance despite a strong one-year return, leading to a reassessment of its valuation. The company is considered 27.1% undervalued with a narrative fair value of $17.00, driven by strategic partnerships and expansion in", "url": "https://www.sahmcapital.com/news/content/assessing-amneal-pharmaceuticals-amrx-valuation-after-recent-share-price-weakness-2026-05-14", "source_name": "Sahm", "published_at": "2026-05-13T13:08:48", "published_display": "13 May 2026 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) director Deborah Autor sells 34,819 shares at $12.94 avg", "summary": "Amneal Pharmaceuticals director Deborah M. Autor sold 34,819 shares of Class A Common Stock on May 11, 2026, at a weighted average price of $12.94 per share. Following this open-market transaction, her direct holdings in the company amount to 93,660 shares. The sale, valued at ap", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-c5cac0f5b905.html", "source_name": "Stock Titan", "published_at": "2026-05-12T20:09:47", "published_display": "12 May 2026 20:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (NYSE: AMRX) director settles RSUs, now holds 128,479 shares", "summary": "Amneal Pharmaceuticals director Deborah M. Autor increased her equity stake by converting 34,819 restricted stock units into Class A Common Stock on May 7, 2026. This transaction brought her direct holdings to 128,479 Class A shares. Additionally, she was granted 19,824 new restr", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-655c18040324.html", "source_name": "Stock Titan", "published_at": "2026-05-10T15:40:12", "published_display": "10 May 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugmaker Amneal posts $62M profit as specialty-drug sales rise 23%", "summary": "Amneal Pharmaceuticals reported strong Q1 2026 financial results with net revenue reaching $723 million and GAAP net income of $62 million. The company saw a significant 23% rise in specialty drug sales, driven by key branded products, and affirmed its increased full-year 2026 gu", "url": "https://www.stocktitan.net/news/AMRX/amneal-reports-first-quarter-2026-financial-0dvg5dywpq6z.html", "source_name": "Stock Titan", "published_at": "2026-05-10T03:39:35", "published_display": "10 May 2026 03:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) director Jeffrey George exercises 34,819 RSUs, receives 19,824 new units", "summary": "Amneal Pharmaceuticals director Jeffrey P. George recently engaged in equity compensation activities. He exercised 34,819 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common Stock, bringing his direct holdings to 344,614 shares. Additionally, on May ", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-1c7fbdb1d3d3.html", "source_name": "Stock Titan", "published_at": "2026-05-09T15:38:53", "published_display": "09 May 2026 15:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals (AMRX) Profit Rebound Challenges Concerns Over Earnings Quality", "summary": "Amneal Pharmaceuticals (AMRX) reported a profit rebound in FY 2025, with net income swinging to US$72.1 million, but the presence of a US$58.0 million one-off loss raises concerns about earnings quality. While a DCF fair value suggests the stock is undervalued, its high P/E ratio", "url": "https://www.sahmcapital.com/news/content/amneal-pharmaceuticals-amrx-profit-rebound-challenges-concerns-over-earnings-quality-2026-05-09", "source_name": "Sahm", "published_at": "2026-05-09T10:39:03", "published_display": "09 May 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (NYSE: AMRX) director exercises 34,819 RSUs and receives new grant", "summary": "Amneal Pharmaceuticals director J. Kevin Buchi exercised 34,819 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common shares at no cost, increasing his direct holdings to 75,077 shares. He also received a new grant of 19,824 RSUs on May 6, 2026. This a", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-27aa8c93aae6.html", "source_name": "Stock Titan", "published_at": "2026-05-09T10:09:36", "published_display": "09 May 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Reports First Quarter 2026 Financial Results", "summary": "Amneal Pharmaceuticals reported a strong start to 2026, with first-quarter net revenue of $723 million, GAAP net income of $62 million, and adjusted EBITDA of $202 million. The company affirmed its previously announced increased full-year 2026 guidance, citing strong performance ", "url": "https://www.manilatimes.net/2026/05/08/tmt-newswire/globenewswire/amneal-reports-first-quarter-2026-financial-results/2338889", "source_name": "The Manila Times", "published_at": "2026-05-09T00:10:15", "published_display": "09 May 2026 00:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity", "summary": "Amneal Pharmaceuticals director Gautam Patel increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units into Class A Common Stock at $0.00 per share, bringing his direct ownership to 1,643,963 shares. Additionally, on M", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-955813100fd0.html", "source_name": "Stock Titan", "published_at": "2026-05-08T20:45:46", "published_display": "08 May 2026 20:45", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director boosts stake with 34,819 shares in Amneal (NYSE: AMRX)", "summary": "Amneal Pharmaceuticals director Ted C. Nark increased his equity stake by exercising 34,819 restricted stock units into Class A Common Stock shares on May 7, 2026. This transaction, part of a stock-based compensation, brought his direct holdings to 325,848 shares. Additionally, N", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-832021762541.html", "source_name": "Stock Titan", "published_at": "2026-05-08T20:38:46", "published_display": "08 May 2026 20:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) director exercises RSUs, now holds 260,252 shares", "summary": "Amneal Pharmaceuticals director John Kiely exercised 34,819 restricted stock units (RSUs) on May 7, 2026, receiving an equal number of Class A Common Stock shares at $0.00 per share. He also received a new RSU grant of 19,824 units on May 6, 2026. Following these transactions, Ki", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-e7ba1e52d953.html", "source_name": "Stock Titan", "published_at": "2026-05-08T20:38:46", "published_display": "08 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (NYSE: AMRX) director exercises 48,747 RSUs and receives 30,837-unit grant", "summary": "Amneal Pharmaceuticals director Paul M. Meister recently exercised 48,747 Restricted Stock Units, converting them into Class A shares, increasing his direct holdings to 832,800 shares. Additionally, he was granted a new 30,837 Restricted Stock Unit award. These transactions, deta", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-fbe71281dfe4.html", "source_name": "Stock Titan", "published_at": "2026-05-08T20:38:46", "published_display": "08 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (NYSE: AMRX) director converts RSUs to shares and gets new grant", "summary": "Amneal Pharmaceuticals director Yanai Shlomo increased his equity stake by exercising 34,819 restricted stock units (RSUs) into Class A Common Stock. He also received a new grant of 19,824 restricted stock units, further boosting his potential share ownership in the company. Foll", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-eef54e036799.html", "source_name": "Stock Titan", "published_at": "2026-05-08T20:38:46", "published_display": "08 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals (NASDAQ: AMRX) posts Q1 profit surge and inks $375M Kashiv acquisition", "summary": "Amneal Pharmaceuticals reported a significant surge in Q1 2026 profit, with net income more than tripling to $78.0 million and diluted EPS at $0.19, driven by higher gross margins and strong Specialty segment performance. The company also announced a definitive agreement to acqui", "url": "https://www.stocktitan.net/sec-filings/AMRX/10-q-amneal-pharmaceuticals-inc-quarterly-earnings-report-732ea1b096e1.html", "source_name": "Stock Titan", "published_at": "2026-05-08T10:39:03", "published_display": "08 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQTVk4VndWZ1VFSFBEMHpZZkJZMWJTS3F0bHF2ZFlBZFNpSUg0Tm94UEFVQzgyRkMxTi1TVERYUnMyTVlNRTU5WlJvd1dMc2RKZzIxdXhYV0h0VVZ4R2JaWVliZVRWcUM4Si1HLW5acU5PN2Nqd3RtNVhxNi16UFVyNVVjTm02Mmx3MXFDYjRpaHB6ZHZwMTFnYnhnYw?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Do Options Traders Know Something About Amneal Stock We Don't?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNeUZhWlB5RmxBakhSeHFEQ3lQT2d0SmFEY24zWTg0NXpndFBOVjBXOXNOVHBXUVNHSFhVR3RkYXl2SWZUZkg2dEx5MnBXZDRqLWVqSHI4bkJXdVZmOTh4VUZjOXB4RHdfSnZvTlhkUkxYY0lLZWF3TXV4NUc0RGp0dHJKdXFLRHc0UWpYUUVQUWg5djlfMjhHejZHZlNQNmRjY21HcEVn?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think \"Yes\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQTTNBSzdOWnZ1S2p5SlpaUVZCVjNIOWtOVkFrRVBySGdLdGhpeDA5aDMxcFl1eVJtYTE1aUFzd1VTU3V2TmczQ0I5UkVFNW5tWE1DdURhT19FY3hnSU1lN19Vb0d5NW5SUVhSWjhRSW1NVlVHLUlwNFFDamtRcVNmdFFZR2dmS3dxU1NTSVRiaW10Ni1IMndKZmJ5UQ?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Returns And Recent Share Price Cooldown", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNZkVfZlIzQ1Q1RGwtcnl0LW53VUoyTWhmSjlpSnRpQnJSTjVFSWFySmROZ2xfN0xJYjZHMWlvdHlXTDlNajY4NXF5dzNOYnd0NWZNZ1ZadXJWdWdETzJFWFVDRDJZX2xzMjFTR2xqOHUtSHktdERnWUR2cm12NVZCTXZsc1l6bnNERnNhaWFTYXhPMmtFOUI4a2FGTS1aM0pJYVRjYzBuU3R5ejhONGJheEZR?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal bets on Kashiv to expand affordable biologic medicines", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPSUZwb2h0ODRhQkItSHBRdWdTMEpTSlVONTZMM01yXzJNN1M2THpNR25pdUhrRVY5MDhhaUVOVG1XYkRyd3pRY1lvMUhBckJIMDJYSVhWRkZwZjBSakY1MldTenV6aEdPZzUzem9zTkdsTlFqeWRPRlpYMm9qbXl3ckd0MUhwWThZVzRoSWktQTRVTHVMc3MxQUF4VEU4QUdId1BXOG5TM2RrMUk3WHhKUTBzcVZWbWtPdmZuODEtVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Agrees to Acquire Kashiv BioSciences to Create", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AJBVV95cUxNSGptOGdhSWZuR2dsd1l2SDZhM3drUVlQZTVzbDllTGpUN1J0OUl0V1ZJWU9fVHFpcnh5WWkzQ2FxczdzWmNEUEVvYlJTeGVBdzllV3FiRV9UM2xGNU5tTWJtUTRaakY3bXN4Q1J6MEpiZWQ1enZjdlI5ZkhrSWJ6M2U3UEc3NmlnbkZmbmREcTJobXBKa1czeTZneG0xekYwSGlfVkhXQ1NZZWJuWGlqX3dORTEwNGFlcERrZ0s2VlJGTUdzcXRPOWJ3aWlOcVJ4RW13cHR5NVVLRjNSQVRtUklndFFIMVdOYkw2VldzWXhIVnVxLXBPQnl5TC1yWkRud0xUbzR1aTRIeF9HOUxFcWNZS1h5MUM4M0ZoS0lIYmJKWVBZVDlZYWl3cXAtOXhZdTBEVHFBeVRxQk5CbHRkSXBjMHVOQU9wckJUSUNnbE9BTzUxakUxZHltMXRDVnQ3aHJxOFlpRlE0Y0Zq?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AMRX Stock Undervalued? Sales Multiple, Target, Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQUWxSRjVjdDNJcEdTajE1Qlg1N0taM1dKOFZNSDdQSlBhTnQzWmxQQ0FOWjZ3eWlnRjNiQVl2Nk5JcEhOZ21FS3pCMU9RUEZnUGxQTVdabzNBMmgyZW1yM2ZYVW41TU9GaE5MY2tTZm5HZkJuQ3dzQk5UYmw0V01Tcmh6OXE3ZnBYSm40RzJuMmtMT2FpalZqaTlUSThBNmpReWNucA?oc=5", "source_name": "Market source", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxObTFtWGswb0RMNVEzTE9rSXk3NEJoWi1XQWNiNFFLZENvdTFRd0FnVG8za1VZclRMbF9GOG51RWNland6RC10WVhYOHZreXNZbHdEM3RWNVJDNVhtazJ1SnQzRHMxbVRDbkNVbElwY3p5c0I2YU90OFM4bldoZlJwdkxYMTVsbG5YLTN5U2EtdHljTm96cHlDYmZPdm1nS2JveGZFZFhjLTg5dTdCZlZQNXI1LWdJSmdLa25Gb0ZiWQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal co-chief to speak at Miami Barclays healthcare investor event", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQUE5OWkFPRU9KU1MwTUU2NF9TU1ZZamUwLUhUbEtnWjk5dDg5SzhMZW0zb3dUcDVIUklkZUFvY2xTZlctTEN4LXViU2dmN29lZ3BiS2tFYWx0QVpJRE1XczA3T3doZW0ta0M4R0EwdER4V3JMbGZ3aE5NTC1rR29hTXBGZFo3U2hERVpmZ0VobDdUN05leGpkTFNwT29Edw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals Reports Strong Full Year 2025 Financial Results and Confident 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQVVdfVTV6N3NNVGhQSmNoRl8yRk9WQjVrV0IwQlp2OUxkbk53MVJ0WUVNeVBCY1FFalJhXzNvd3BzbUNrSUJkS1BaQk1pQ1ZGV2FwS2h2UEE2N1R6UXNmODBLaHc5ak55SVRBMmhjVVJsNVNQaHdCZi0tMjZPR1c1VlFaRmhmMVZYOFk2SlQwNUhvSTBKYTdHUkNrSzNHTmxPUkJQN0xYT25FNjFsaUltVThlcXB4eS0ycGtidjQ3ekd1MGJhUGVocTQ2NA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amneal (AMRX) Stock Is Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxObTBMZDB4RGVlcmRLZ2dvSXpnbW1sYWo1V2pydTFmVzNUN0diakc1V2ZpOWpJQjd0SEFXOVJwY25fVjJsOEwwNHI5RUtZd2I2LUdjQWRKempEdk5SbVIxVDd0TmJOUW5hdUtmN0xXTUpwX3ZxZ29QdGdDTVRpd2hKQQ?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals Inc. (AMRX) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE44RFpwZzRIenZSZFNOaERXUWV0SXY0NGhXcW04dEpJc3JncmREMmVFV254YkhrSjZ5amRfY0pUOUZoU21vTWs5NTkySlVHenloYjZ0dlQ0OA?oc=5", "source_name": "Gotrade", "published_at": "2026-02-03T05:11:03+00:00", "published_display": "03 Feb 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugmaker Amneal joins S&P small-cap index investors track", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNSk9Scm9CR1VPdlQ5NVhrVW1lYjd1OVJGM3o4SmlXUUFscERiSTJ4eTRmNGE0Wkl0NWh3VmxfMmpId2owRlNFWkhXQlFRUmVid2FNSHVmXzhYWVhOU2tYaXpCSnc5djI3ZWo2U1owbUUyMzJLUXF5ZTRPY1ZCNUIxcnVEdkpDNFRvQnhqX3RQNjJCR05OdjR1dUNQWExrNFlsZUJsYUxkQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-21T17:26:16+00:00", "published_display": "21 Jun 2026 17:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/korro-bio-inc-krro-soars-120600350.html", "source_name": "Zacks", "published_at": "2026-06-19T12:06:00+00:00", "published_display": "19 Jun 2026 12:06", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) agrees to buy Kashiv for $375M cash plus equity and milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQMmxra2dRTkc1Mjl1T1BzcktuOUdKVjFRMEJiQkI2NUgxQnk4QlZyQ0lsT3Q0NWQ2S2xOVExkVVlXTlZuOXZ4X2Y5SVZHMVJ2cTd4NUtPZXFTWS1zY2xsMHhVZ25NMG1HdEZTQzg5WE01NkdzTk9mSDZOYUNZdko5YjNXcmhIdVh4V3RqU3UxcE83MFZySU92SkFCeUpENE1MaXJIT1owRE55UGZvbzBQLVBBRjdfRUV5NkNRbWxaTTRLRFNFZFgzY2g2TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T21:00:28+00:00", "published_display": "18 Jun 2026 21:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/1-small-cap-stock-long-111651197.html", "source_name": "StockStory", "published_at": "2026-06-17T11:16:51+00:00", "published_display": "17 Jun 2026 11:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top 3 Health Care Stocks That May Collapse This Quarter", "summary": "The article identifies three healthcare stocks\u2014Cardinal Health, TG Therapeutics, and Amneal Pharmaceuticals\u2014that may be overbought according to the Relative Strength Index (RSI) as of June 15, 2026. Despite recent positive news and stock gains for all three companies, their high ", "url": "https://www.sahmcapital.com/news/content/top-3-health-care-stocks-that-may-collapse-this-quarter-2026-06-15", "source_name": "Sahm", "published_at": "2026-06-15T16:39:17", "published_display": "15 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) Stock Valuation Check After Strong Multi Period Gains And Conflicting Fair Value Models", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPV3k1VFp2RVk5dUdoV0tMZmtBTzd0bkpGZkx5TlRqV0ZNdWVwM2lmTlFCZDl0Q2o1bm5mdE0yUXhfejZXOW1GZ3h6VWdzUzM4Rk5FU3ZVQWsyaWhlak1VU2RmNm5YQno0VDVIdzhoUUF5SG82V21panZsdklqS3Y1Y2dxbVcxYW93U2ZScjY2RDlFbl9tdjZXdUJYT3U4RUhUZWZTSGJvR2VrWlNFXzVHN0ltMDFBNUdkVWwzbG00ZXE2Q2lWVDQweTBSaTlReVFCRm9hbDJYXzREOHVKODRGeTUtU3ZnRDhLc1Aw0gHwAUFVX3lxTFBFWGdfcmxBMGtBWTBtcld5VzlyMzdjTzFzMEowVEJnVUhTN0xDbmVJcTBRQVppQ1pUdXJrWnJLMk5DS3Q3a1BGMEhPTV9wUEx2NTFUanlNWnJ0YjdBT0ZkdlU5UlVQTjk4ekhxSUdwV0NwcXZFUWV2NkNWcGNNdTV2bDBPclpLRnlfZDFuZm1uTk0wUnpqb2xCeHRXekxrNG1hTlFNRUlIOVFzZ2NtRGR6a1JTTkIyNThqSUdZZ3NXTkkzUGg2QzhFb2cwQjBnOGhnV25scWdNU1Y5UjU0RHlvZFFVWHgwc0RfQ0pUSm84dQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals (AMRX) Is Up 17.8% After CREXONT Phase 4 Gains And New Oncology Launch", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/amneal-pharmaceuticals-amrx-17-8-050712031.html", "source_name": "Simply Wall St.", "published_at": "2026-06-13T05:07:12+00:00", "published_display": "13 Jun 2026 05:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals (AMRX) Is Up 19.0% After CREXONT Data And New CGT Oncology Approval - What's Changed", "summary": "Amneal Pharmaceuticals (AMRX) recently saw a 19.0% stock increase following positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson\u2019s disease and FDA approval for its romidepsin injection for cutaneous T-cell lymphoma. These developments reinforce the company's strat", "url": "https://www.sahmcapital.com/news/content/amneal-pharmaceuticals-amrx-is-up-190-after-crexont-data-and-new-cgt-oncology-approval-whats-changed-2026-06-11", "source_name": "Sahm", "published_at": "2026-06-11T14:12:02", "published_display": "11 Jun 2026 14:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD", "summary": "Amneal Pharmaceuticals (AMRX) stock reached a 52-week high of $15.44, experiencing an 88% increase over the past year. This surge is attributed to the company's strong financial performance, including exceeding Q1 2026 earnings and revenue expectations, and key product developmen", "url": "https://www.investing.com/news/company-news/amneal-pharmaceuticals-stock-hits-52week-high-at-1544-usd-93CH-4735567", "source_name": "Investing.com", "published_at": "2026-06-11T12:39:53", "published_display": "11 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQUUh2NHdvREcwdWFlQ3FKakpRS2N0MTdzb2hoQ29RbFBxQnFpcTlJY0JBd2hObGx2X2N1TThZclZsRGVKWlRKT0N4UXZVU2hpLTFsNHBoSkQwS1lSZHFseTNjcjNfNTV6TWFoRXBHV0JBaXlkQXlJYXVzWC0zYzdnbEQyT1JLZHQwRWMyVTZVbkFLQmphd29Db0ZYQW1wa1JIbXZ3?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD By Investing.com", "summary": "Amneal Pharmaceuticals Inc. Class A stock reached a 52-week high of $15.44, trading at $15.45 with a market capitalization of $4.87 billion, reflecting an 88% increase over the past year. This surge is attributed to the company's strong financial health and recent positive develo", "url": "https://ng.investing.com/news/company-news/amneal-pharmaceuticals-stock-hits-52week-high-at-1544-usd-93CH-2552288", "source_name": "Investing.com Nigeria", "published_at": "2026-06-11T07:09:59", "published_display": "11 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dispensary of Hope Launches \"Hope Alliance\" Campaign with Support from Amneal Pharmaceuticals", "summary": "Dispensary of Hope has launched its \"Hope Alliance\" campaign, aimed at expanding access to longer-dated medications for low-income and uninsured patients nationwide. Amneal Pharmaceuticals is the first manufacturer to commit significant support, ensuring a reliable supply of crit", "url": "https://www.sahmcapital.com/news/content/dispensary-of-hope-launches-hope-alliance-campaign-with-support-from-amneal-pharmaceuticals-2026-06-10", "source_name": "Sahm", "published_at": "2026-06-10T14:09:18", "published_display": "10 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase", "summary": "", "url": "https://finance.yahoo.com/m/2b12215f-513a-3347-ac82-994df2ad5b8a/amneal-pharmaceuticals-bets.html", "source_name": "MarketBeat", "published_at": "2026-06-09T19:05:48+00:00", "published_display": "09 Jun 2026 19:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving Amneal's 2026 Growth Outlook?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPcWlSODh4a2RjOFhhSVo2VGNJSGZpUWQ0MmxaREQ5Y3U4NzM5SDQyd3M2aGc1NWIxRVhmdVNrZUI5Rzg0YmpyemFOUG1LamlhR0pTQUZuZ3JpRzBxVk40aHFGXy1TZm9BY0wwMERBNlBfaDdUZThxT2R4N1lSYzh5SEZZNEdWei16V1lFOWRWc0pkMTh5bWxXQkVHMVhxNk1P?oc=5", "source_name": "TradingView", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data", "summary": "Amneal Pharmaceuticals (AMRX) recently received FDA approval for its romidepsin injection and positive interim Phase 4 data for Parkinson's treatment CREXONT, contributing to an 80.45% 1-year total shareholder return. Despite being valued at $13.75 against an estimated fair value", "url": "https://www.sahmcapital.com/news/content/a-look-at-amneal-pharmaceuticals-amrx-valuation-after-romidepsin-approval-and-positive-crexont-trial-data-2026-06-06", "source_name": "Sahm", "published_at": "2026-06-06T10:39:38", "published_display": "06 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/amneal-pharmaceuticals-amrx-story-shifting-050559676.html", "source_name": "Simply Wall St.", "published_at": "2026-06-06T05:05:59+00:00", "published_display": "06 Jun 2026 05:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX)", "summary": "Amneal Pharmaceuticals (AMRX) shares advanced after the company secured FDA clearance for its generic version of a cancer treatment. The approval is for a bendamustine hydrochloride injection, a chemotherapy drug used to treat chronic lymphocytic leukemia and indolent B-cell non-", "url": "https://www.msn.com/en-us/health/other/amneal-pharmaceuticals-advances-after-securing-fda-clearance-for-cancer-treatment-amrx/ar-AA24QznW", "source_name": "MSN", "published_at": "2026-06-05T21:39:58", "published_display": "05 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Stock Up on FDA Nod for Romidepsin Injection Solution", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/amneal-stock-fda-nod-romidepsin-153000754.html", "source_name": "Zacks", "published_at": "2026-06-05T15:30:00+00:00", "published_display": "05 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals stock gains on FDA approval for cancer drug By Investing.com", "summary": "Amneal Pharmaceuticals (NASDAQ:AMRX) shares rose after the FDA approved its romidepsin injection solution for cutaneous T-cell lymphoma, granting 180 days of market exclusivity. This ready-to-use formulation offers an alternative to a previously withdrawn product and generated ap", "url": "https://au.investing.com/news/stock-market-news/amneal-pharmaceuticals-stock-gains-on-fda-approval-for-cancer-drug-93CH-4472078", "source_name": "Investing.com Australia", "published_at": "2026-06-05T10:39:38", "published_display": "05 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals stock gains on FDA approval for cancer drug", "summary": "Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) saw its shares rise in premarket trading after receiving FDA approval for its romidepsin injection solution. This drug, a histone deacetylase inhibitor for cutaneous T-cell lymphoma, offers a ready-to-use alternative and is eligible for 1", "url": "https://m.investing.com/news/stock-market-news/amneal-pharmaceuticals-stock-gains-on-fda-approval-for-cancer-drug-93CH-4726690?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-04T12:09:40", "published_display": "04 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amneal (AMRX) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNa0dfRXF6MXBqZDFYNjRGb2pzNWcwUjdiUFVvMG5CWXFhUmVWdVA3RlkxdnI0YXhxMEtubXNYelgyOVF0LVI4ZDd3TW45akZjT2J6Z0YzcGZtOXNxQWRjZjBUR056R1Rvb1RIdDd4dElheDB4MjhCLTdHLW1aY1pyalZ0RzFqYS1mR0pLMzF4VEt4QWN0VmliaU1GcmowaGZST0xiQ2hjUU5YMlJScmF6Qk0zNm96bE8weTFSTDZXTnk4T2Z3?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal\u2019s Goldman Sachs 2026 healthcare talk to stream live June 9", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOU1E2LWtVMjRlbUZadWppaXltU2hEN19wTW1wVlk3ZzFzam5Pb2NRWjdyVS14TGF4R3RpckIyd1NrZnF2YnVrdExrZ29pNG5QWlpsZE1vU3B0N2EwZUZnYnVocUxLWWp6ZlNpZ0g2ZkNxaVdLSGNaek1uMVlac1hlRnVVWkhOZDVhQ0c2dEdFQV90UVlhbjhHYmVLSFNRU2FTWVN0eWpDOHBHNUkzOUJBek1PS3E0MVYxSk5jczBaSjM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNNWZuNGpuV3hudUNTV1RCZFV5dDlNc2J6YU9YdjNRdm5LS085cWVWMmdtckZITlpETVVjVDNLeTI5U0t1TmdxejQweno3RU5GVDJuQ3dWN2ZMTmZSTVZLY2dSUmhZS0JKeUlJTWthc1MweFlhSTdFU2x2YW9Famh2RHZEVG4tb04yYnRreE82MlBlSlpnRE1jSHllZkFzTGxjeU8wSXZhUTJnMVotcDdj?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Strength And Long Term Gains", "summary": "Amneal Pharmaceuticals (AMRX) has seen recent gains and strong long-term returns, prompting an assessment of its valuation. Simply Wall St estimates a fair value of $17.00, suggesting the stock is currently undervalued at its trading price of $13.17. This bullish outlook is drive", "url": "https://www.sahmcapital.com/news/content/assessing-amneal-pharmaceuticals-amrx-valuation-after-recent-share-price-strength-and-long-term-gains-2026-05-30", "source_name": "Sahm", "published_at": "2026-05-29T09:08:57", "published_display": "29 May 2026 09:08", "sentiment": "positive", "sentiment_pct": 64, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYkpzQXJERWVndUxLQ0xoZHVLR3N5WW1aRjJ1QVVKMHZmZlVfM05XTzY3bjdNVUpiYzVuY19YN0o0MUJHLVREeTdSWmJ4YUhaVXVndXlkX05uNHRBNXdOSm1HbnVKYUpvYmJaUkdfV29lVU9MNjFkRWR0TUhFZnVaOXlwcEZTVndfajR2LVVqRE9VNHpqLUhNT3pfc04tTGVSVjZXNWNBSFE?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQ0ZnM0YtZFBWeGNmVnFZTlBZdVlxbWpWVkZFaGtrcGExZHdjb0t5ZXJRbjBlaVRWd0NybVdvYVAxZVhtSTJEWWFrMDM5T2V0aU9RcFhUcWw5b1QtcHZXcElsR1oxbE92MUlYakQ2U2tNd282S2lPdVB4RGo2aW5Iby1aTXdpN0lIVnFYdk8wRnphb2c3dEkwVWpUajJXSWM4SFYxM1laM3RkMWs?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNZGdxTjJUSWU4cUU5X3ptZ183Q2VyQk43RFZhZXl1REN3V21zckN5RVE5SGFidHZtTTQxeEVXS0hZQjdnNi1QaFNlZXhNbWpaQ2lROUVqdjZxTHl2TmRtQ1c4RWplc2c4NUlFXzdFMzVlV2tBSlQ3LU43Tl9LSFUzLVRPYXNmSUp4dndVS0RQclhqUUpxS3NVZWtPSQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2 Reasons AMRX is Risky and 1 Stock to Buy Instead", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQY2x0ZE5jalpSS0tjam1RNmhuUWpYdnZVVDlfV1lpWnhqUktqcWwzeE94Z3BRcFRTODl4cHVmc0t1V0UwNTRsbHh4MzNqallsVXZqZmU1c3V6UGlURW51bllDZ3J1TjZZREVpR2NFdFRrUlIxQWRZM3pBejAtZ2IxOGVfcTFiZ1Jvc2JoNk45VlQ?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Amneal Pharmaceuticals, Inc. SEC Filing", "summary": "This article details an SEC Form 144 filing by Amneal Pharmaceuticals, Inc. (AMRX). The filing indicates a proposed sale of 34,819 shares of Class A Common Stock by an individual through Merrill Lynch on May 11, 2026, with an aggregate market value of 450,416. The shares were acq", "url": "https://www.stocktitan.net/sec-filings/AMRX/144-amneal-pharmaceuticals-inc-sec-filing-1cabdad0fc62.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:40:23", "published_display": "13 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness", "summary": "Amneal Pharmaceuticals (AMRX) has experienced mixed share performance despite a strong one-year return, leading to a reassessment of its valuation. The company is considered 27.1% undervalued with a narrative fair value of $17.00, driven by strategic partnerships and expansion in", "url": "https://www.sahmcapital.com/news/content/assessing-amneal-pharmaceuticals-amrx-valuation-after-recent-share-price-weakness-2026-05-14", "source_name": "Sahm", "published_at": "2026-05-13T13:08:48", "published_display": "13 May 2026 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) director Deborah Autor sells 34,819 shares at $12.94 avg", "summary": "Amneal Pharmaceuticals director Deborah M. Autor sold 34,819 shares of Class A Common Stock on May 11, 2026, at a weighted average price of $12.94 per share. Following this open-market transaction, her direct holdings in the company amount to 93,660 shares. The sale, valued at ap", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-c5cac0f5b905.html", "source_name": "Stock Titan", "published_at": "2026-05-12T20:09:47", "published_display": "12 May 2026 20:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (NYSE: AMRX) director settles RSUs, now holds 128,479 shares", "summary": "Amneal Pharmaceuticals director Deborah M. Autor increased her equity stake by converting 34,819 restricted stock units into Class A Common Stock on May 7, 2026. This transaction brought her direct holdings to 128,479 Class A shares. Additionally, she was granted 19,824 new restr", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-655c18040324.html", "source_name": "Stock Titan", "published_at": "2026-05-10T15:40:12", "published_display": "10 May 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugmaker Amneal posts $62M profit as specialty-drug sales rise 23%", "summary": "Amneal Pharmaceuticals reported strong Q1 2026 financial results with net revenue reaching $723 million and GAAP net income of $62 million. The company saw a significant 23% rise in specialty drug sales, driven by key branded products, and affirmed its increased full-year 2026 gu", "url": "https://www.stocktitan.net/news/AMRX/amneal-reports-first-quarter-2026-financial-0dvg5dywpq6z.html", "source_name": "Stock Titan", "published_at": "2026-05-10T03:39:35", "published_display": "10 May 2026 03:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) director Jeffrey George exercises 34,819 RSUs, receives 19,824 new units", "summary": "Amneal Pharmaceuticals director Jeffrey P. George recently engaged in equity compensation activities. He exercised 34,819 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common Stock, bringing his direct holdings to 344,614 shares. Additionally, on May ", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-1c7fbdb1d3d3.html", "source_name": "Stock Titan", "published_at": "2026-05-09T15:38:53", "published_display": "09 May 2026 15:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals (AMRX) Profit Rebound Challenges Concerns Over Earnings Quality", "summary": "Amneal Pharmaceuticals (AMRX) reported a profit rebound in FY 2025, with net income swinging to US$72.1 million, but the presence of a US$58.0 million one-off loss raises concerns about earnings quality. While a DCF fair value suggests the stock is undervalued, its high P/E ratio", "url": "https://www.sahmcapital.com/news/content/amneal-pharmaceuticals-amrx-profit-rebound-challenges-concerns-over-earnings-quality-2026-05-09", "source_name": "Sahm", "published_at": "2026-05-09T10:39:03", "published_display": "09 May 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (NYSE: AMRX) director exercises 34,819 RSUs and receives new grant", "summary": "Amneal Pharmaceuticals director J. Kevin Buchi exercised 34,819 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common shares at no cost, increasing his direct holdings to 75,077 shares. He also received a new grant of 19,824 RSUs on May 6, 2026. This a", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-27aa8c93aae6.html", "source_name": "Stock Titan", "published_at": "2026-05-09T10:09:36", "published_display": "09 May 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Reports First Quarter 2026 Financial Results", "summary": "Amneal Pharmaceuticals reported a strong start to 2026, with first-quarter net revenue of $723 million, GAAP net income of $62 million, and adjusted EBITDA of $202 million. The company affirmed its previously announced increased full-year 2026 guidance, citing strong performance ", "url": "https://www.manilatimes.net/2026/05/08/tmt-newswire/globenewswire/amneal-reports-first-quarter-2026-financial-results/2338889", "source_name": "The Manila Times", "published_at": "2026-05-09T00:10:15", "published_display": "09 May 2026 00:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity", "summary": "Amneal Pharmaceuticals director Gautam Patel increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units into Class A Common Stock at $0.00 per share, bringing his direct ownership to 1,643,963 shares. Additionally, on M", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-955813100fd0.html", "source_name": "Stock Titan", "published_at": "2026-05-08T20:45:46", "published_display": "08 May 2026 20:45", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director boosts stake with 34,819 shares in Amneal (NYSE: AMRX)", "summary": "Amneal Pharmaceuticals director Ted C. Nark increased his equity stake by exercising 34,819 restricted stock units into Class A Common Stock shares on May 7, 2026. This transaction, part of a stock-based compensation, brought his direct holdings to 325,848 shares. Additionally, N", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-832021762541.html", "source_name": "Stock Titan", "published_at": "2026-05-08T20:38:46", "published_display": "08 May 2026 20:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) director exercises RSUs, now holds 260,252 shares", "summary": "Amneal Pharmaceuticals director John Kiely exercised 34,819 restricted stock units (RSUs) on May 7, 2026, receiving an equal number of Class A Common Stock shares at $0.00 per share. He also received a new RSU grant of 19,824 units on May 6, 2026. Following these transactions, Ki", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-e7ba1e52d953.html", "source_name": "Stock Titan", "published_at": "2026-05-08T20:38:46", "published_display": "08 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (NYSE: AMRX) director exercises 48,747 RSUs and receives 30,837-unit grant", "summary": "Amneal Pharmaceuticals director Paul M. Meister recently exercised 48,747 Restricted Stock Units, converting them into Class A shares, increasing his direct holdings to 832,800 shares. Additionally, he was granted a new 30,837 Restricted Stock Unit award. These transactions, deta", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-fbe71281dfe4.html", "source_name": "Stock Titan", "published_at": "2026-05-08T20:38:46", "published_display": "08 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (NYSE: AMRX) director converts RSUs to shares and gets new grant", "summary": "Amneal Pharmaceuticals director Yanai Shlomo increased his equity stake by exercising 34,819 restricted stock units (RSUs) into Class A Common Stock. He also received a new grant of 19,824 restricted stock units, further boosting his potential share ownership in the company. Foll", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-eef54e036799.html", "source_name": "Stock Titan", "published_at": "2026-05-08T20:38:46", "published_display": "08 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals (NASDAQ: AMRX) posts Q1 profit surge and inks $375M Kashiv acquisition", "summary": "Amneal Pharmaceuticals reported a significant surge in Q1 2026 profit, with net income more than tripling to $78.0 million and diluted EPS at $0.19, driven by higher gross margins and strong Specialty segment performance. The company also announced a definitive agreement to acqui", "url": "https://www.stocktitan.net/sec-filings/AMRX/10-q-amneal-pharmaceuticals-inc-quarterly-earnings-report-732ea1b096e1.html", "source_name": "Stock Titan", "published_at": "2026-05-08T10:39:03", "published_display": "08 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQTVk4VndWZ1VFSFBEMHpZZkJZMWJTS3F0bHF2ZFlBZFNpSUg0Tm94UEFVQzgyRkMxTi1TVERYUnMyTVlNRTU5WlJvd1dMc2RKZzIxdXhYV0h0VVZ4R2JaWVliZVRWcUM4Si1HLW5acU5PN2Nqd3RtNVhxNi16UFVyNVVjTm02Mmx3MXFDYjRpaHB6ZHZwMTFnYnhnYw?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Do Options Traders Know Something About Amneal Stock We Don't?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNeUZhWlB5RmxBakhSeHFEQ3lQT2d0SmFEY24zWTg0NXpndFBOVjBXOXNOVHBXUVNHSFhVR3RkYXl2SWZUZkg2dEx5MnBXZDRqLWVqSHI4bkJXdVZmOTh4VUZjOXB4RHdfSnZvTlhkUkxYY0lLZWF3TXV4NUc0RGp0dHJKdXFLRHc0UWpYUUVQUWg5djlfMjhHejZHZlNQNmRjY21HcEVn?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think \"Yes\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQTTNBSzdOWnZ1S2p5SlpaUVZCVjNIOWtOVkFrRVBySGdLdGhpeDA5aDMxcFl1eVJtYTE1aUFzd1VTU3V2TmczQ0I5UkVFNW5tWE1DdURhT19FY3hnSU1lN19Vb0d5NW5SUVhSWjhRSW1NVlVHLUlwNFFDamtRcVNmdFFZR2dmS3dxU1NTSVRiaW10Ni1IMndKZmJ5UQ?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Returns And Recent Share Price Cooldown", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNZkVfZlIzQ1Q1RGwtcnl0LW53VUoyTWhmSjlpSnRpQnJSTjVFSWFySmROZ2xfN0xJYjZHMWlvdHlXTDlNajY4NXF5dzNOYnd0NWZNZ1ZadXJWdWdETzJFWFVDRDJZX2xzMjFTR2xqOHUtSHktdERnWUR2cm12NVZCTXZsc1l6bnNERnNhaWFTYXhPMmtFOUI4a2FGTS1aM0pJYVRjYzBuU3R5ejhONGJheEZR?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal bets on Kashiv to expand affordable biologic medicines", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPSUZwb2h0ODRhQkItSHBRdWdTMEpTSlVONTZMM01yXzJNN1M2THpNR25pdUhrRVY5MDhhaUVOVG1XYkRyd3pRY1lvMUhBckJIMDJYSVhWRkZwZjBSakY1MldTenV6aEdPZzUzem9zTkdsTlFqeWRPRlpYMm9qbXl3ckd0MUhwWThZVzRoSWktQTRVTHVMc3MxQUF4VEU4QUdId1BXOG5TM2RrMUk3WHhKUTBzcVZWbWtPdmZuODEtVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Agrees to Acquire Kashiv BioSciences to Create", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AMRX Stock Undervalued? Sales Multiple, Target, Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQUWxSRjVjdDNJcEdTajE1Qlg1N0taM1dKOFZNSDdQSlBhTnQzWmxQQ0FOWjZ3eWlnRjNiQVl2Nk5JcEhOZ21FS3pCMU9RUEZnUGxQTVdabzNBMmgyZW1yM2ZYVW41TU9GaE5MY2tTZm5HZkJuQ3dzQk5UYmw0V01Tcmh6OXE3ZnBYSm40RzJuMmtMT2FpalZqaTlUSThBNmpReWNucA?oc=5", "source_name": "Market source", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxObTFtWGswb0RMNVEzTE9rSXk3NEJoWi1XQWNiNFFLZENvdTFRd0FnVG8za1VZclRMbF9GOG51RWNland6RC10WVhYOHZreXNZbHdEM3RWNVJDNVhtazJ1SnQzRHMxbVRDbkNVbElwY3p5c0I2YU90OFM4bldoZlJwdkxYMTVsbG5YLTN5U2EtdHljTm96cHlDYmZPdm1nS2JveGZFZFhjLTg5dTdCZlZQNXI1LWdJSmdLa25Gb0ZiWQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal co-chief to speak at Miami Barclays healthcare investor event", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQUE5OWkFPRU9KU1MwTUU2NF9TU1ZZamUwLUhUbEtnWjk5dDg5SzhMZW0zb3dUcDVIUklkZUFvY2xTZlctTEN4LXViU2dmN29lZ3BiS2tFYWx0QVpJRE1XczA3T3doZW0ta0M4R0EwdER4V3JMbGZ3aE5NTC1rR29hTXBGZFo3U2hERVpmZ0VobDdUN05leGpkTFNwT29Edw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals Reports Strong Full Year 2025 Financial Results and Confident 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQVVdfVTV6N3NNVGhQSmNoRl8yRk9WQjVrV0IwQlp2OUxkbk53MVJ0WUVNeVBCY1FFalJhXzNvd3BzbUNrSUJkS1BaQk1pQ1ZGV2FwS2h2UEE2N1R6UXNmODBLaHc5ak55SVRBMmhjVVJsNVNQaHdCZi0tMjZPR1c1VlFaRmhmMVZYOFk2SlQwNUhvSTBKYTdHUkNrSzNHTmxPUkJQN0xYT25FNjFsaUltVThlcXB4eS0ycGtidjQ3ekd1MGJhUGVocTQ2NA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amneal (AMRX) Stock Is Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxObTBMZDB4RGVlcmRLZ2dvSXpnbW1sYWo1V2pydTFmVzNUN0diakc1V2ZpOWpJQjd0SEFXOVJwY25fVjJsOEwwNHI5RUtZd2I2LUdjQWRKempEdk5SbVIxVDd0TmJOUW5hdUtmN0xXTUpwX3ZxZ29QdGdDTVRpd2hKQQ?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amneal Pharmaceuticals Inc. (AMRX) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE44RFpwZzRIenZSZFNOaERXUWV0SXY0NGhXcW04dEpJc3JncmREMmVFV254YkhrSjZ5amRfY0pUOUZoU21vTWs5NTkySlVHenloYjZ0dlQ0OA?oc=5", "source_name": "Gotrade", "published_at": "2026-02-03T05:11:03+00:00", "published_display": "03 Feb 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugmaker Amneal joins S&P small-cap index investors track", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNSk9Scm9CR1VPdlQ5NVhrVW1lYjd1OVJGM3o4SmlXUUFscERiSTJ4eTRmNGE0Wkl0NWh3VmxfMmpId2owRlNFWkhXQlFRUmVid2FNSHVmXzhYWVhOU2tYaXpCSnc5djI3ZWo2U1owbUUyMzJLUXF5ZTRPY1ZCNUIxcnVEdkpDNFRvQnhqX3RQNjJCR05OdjR1dUNQWExrNFlsZUJsYUxkQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 92, "total_relevant": 69, "sentiment_summary": {"positive": 30, "negative": 2, "neutral": 37, "score": 59, "total": 69, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 21.6, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 9.3, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 30, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 16.21, "latest_week": "2026-06-19", "one_week_move": 0.1, "four_week_move": 30.5, "twelve_week_move": 36.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.519184, "market_dynamics_buy_signal": false, "relative_strength": 15.608493, "fair_value_gap": 97.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.1308, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +30.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 58, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 17}, {"label": "Market source", "count": 12}, {"label": "Sahm", "count": 7}, {"label": "simplywall.st", "count": 2}, {"label": "Zacks", "count": 2}, {"label": "StockStory", "count": 2}, {"label": "Simply Wall St.", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 69}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 5}, {"label": "Regulatory and legal", "count": 4}, {"label": "Guidance", "count": 3}, {"label": "Balance sheet", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "69", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.1% over one week, +30.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally"}], "updated_at": "2026-06-22T22:45:06.647738+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}